Understanding how blood type affects bleeding and clotting risks
Official title: Defining the Role of Platelet ABO(H) Blood Group Antigens in Hemostasis and Thrombosis
Funded at Brigham and Women's Hospital · NIH-11062030 · Data updated 2026-11-12
This study is looking at how different blood types, especially type O, affect bleeding and clotting in people, to help us understand why some folks bleed more easily while others might have a higher chance of forming blood clots.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $445,708 |
| NIH project number | 1R00HL177820-01 |
| Project ID | NIH-11062030 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with different ABO blood types, particularly those with type O and non-O blood types, who may be at risk for bleeding or clotting disorders.
✕Less likely to help
Patients with blood disorders unrelated to ABO blood group antigens may not benefit from this research.
What this research studies
This research investigates the relationship between ABO blood group antigens and their impact on bleeding and clotting in patients. It aims to understand why individuals with type O blood are more prone to bleeding, while those with non-O blood types are at a higher risk for thrombosis. The study will utilize advanced techniques such as enzyme-linked immunosorbent assays (ELISA) and surface plasmon resonance to analyze how these blood group antigens influence platelet function and binding to critical proteins involved in blood clotting. By defining these mechanisms, the research seeks to provide insights that could lead to improved patient care and treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to better risk assessment and management strategies for patients at risk of bleeding or thrombosis based on their blood type.
How similar studies have gone: Previous research has indicated that blood type can influence bleeding and clotting risks, suggesting that this investigation builds on established findings in the field.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Hollenhorst, Marie — Brigham and Women's Hospital
- Study coordinator: Hollenhorst, Marie
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
Understanding how DVT forms and heals to prevent vein scarring
This NIH grant supports a physician-scientist to study why deep vein clots form and how vein walls get scarred, with the goal of improving long-term outcomes for patients who develop DVT.
-
Piezo1’s role in blood clotting across vessels
Researchers are exploring how a tiny sensor in blood vessels called Piezo1 influences clot formation, with the aim of reducing clotting risks without causing dangerous bleeding.
-
Oscillatory blood flow and vein valve health to prevent clots
Aimed at understanding how the natural rhythmic blood flow in leg veins protects against clots and whether restoring that flow can prevent dangerous vein clots in hospitalized patients.
-
Local anti-inflammatory therapy to help dissolve clots and prevent vein damage in DVT
Aims to test a local anti-inflammatory treatment to help resolve deep vein clots and reduce long-term vein problems in people with DVT.
-
Precision risk tools for blood clots and bleeding in critically ill children
A pediatric-focused project will use existing data from many hospitals to build and test a risk model that helps doctors decide which very sick kids might benefit from clot-prevention therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.